AB0192 EVALUATION OF TEMPOROMANDIBULAR JOINT INVOLVEMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS

Background: Rheumatoid Arthritis (RA) is the most common chronic inflammatory disease usually involves peripheral joints with a symmetric distribution. The temporomandibular joint (TMJ) seldom to be affected first in course. Objectives: Aim of our study describe and assess prevalence (TMJ)disorders patients arthritis (RA). Methods: A cross sectional including RA patients, which consulted or were hospitalized Rheumatology department Taher Sfar Hospital Mahdia Tunisia, during period 10 months. diagnosis was secured by ACR/EULAR 2010, Classification Criteria. clinical TMJ examination performed trained dentist same hospital. We assessed pain VAS (visual analog scale) varies from 0 10. following key parameters evaluated: on TMJs bilateral palpation; sounds (clicking crepitus) opening closing mandible; dysfunction movement alterations. Clinical sociodemographic also determined. Results: Our included 51 an average age 51.11 years ±12.4 [21-74years]. 50patients (92.6%of cases) women 8 (14.8%) diabetic. Only one patient smoker. mean duration 10.7 7.7± [10months-35years]. factor (RF) positive 25 Patients (46.3%of cases). Anti-citrullinated peptide antibody (ACPA) 32 (59.3 %).41patients (75.4%) had radiological impairments 28 (51.9%) specific deformations RA. activity score (DAS28-VS) (DAS28-CRP) respectively 4.1±1.5 [1.4-7.3] 3.4±1.5 [1.24-6.71]. present 29 (56.9 %) which67.7% appeared before ten years. 5 (16.7%) more than 7 that severe pain. involvement 64.3% unilateral 35.7 %. Functional difficulties detected 22 (44.9 %). revealed limitation mouth 11 (21.2 %), alteration 13 (27.79 clicking mobility (81.3 crepitus 1 (6.3%). Disease associated pain(p=0.05) alterations (p=0.04). correlated DAS28 (p=0.02). In we found corticosteroid therapy impact (p=0.01), functional (p=0.01) movements (p=0.004). Conclusion: very rare early phase disease, thus may develop signs symptoms course time. showed frequency disorders important factors Disclosure Interests: None declared